Briefing
CDK4/6 inhibitors with endocrine therapy as neoadjuvant treatment, with ctDNA-guided therapy after surgery
Phase 2 trial of neoadjuvant CDK4/6 inhibitor plus endocrine therapy. The registry says post-surgery treatment is guided by ctDNA status, and the primary outcome is the ctDNA clearance rate after neoadjuvant therapy. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting